Write in a clean editor, then format for ESMO Open in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
ESMO Open is a peer-reviewed journal published by Elsevier, covering Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Advanced Breast Cancer Therapies.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, ESMO Open 12 (2023) 45–58.
Formats any DOI in ESMO Open style. No sign-up. |
| Publishes research in | Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Advanced Breast Cancer Therapies Breast Cancer Treatment Studies HER2/EGFR in Cancer Research |
| ISSN | 2059-7029 |
| Citation impact (2-yr) | 1.46 |
| h-index | 96 |
| i10-index | 1,184 |
| Total citations | 54,573 |
| Article processing charge | $2,965 |
| Open access | Yes |
| Top institutions publishing here | Institut Gustave Roussy |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
When in a patient more than one tumour in the same or a different organ is diagnosed, multiple primary tumours may be present. For epidemiological studies, different definitions of multiple primaries are used with the two main definitions coming from the project Surveillance Epidemiology and End Results and the International Association of Cancer Registries and…
The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively. These receptor tyrosine kinases are expressed in human neuronal tissue and play an essential role in the physiology of development…
PURPOSE: To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC). METHODS: Patients with aRCC with a clear cell component were stratified by International Metastatic Renal Cell Carcinoma Database…
Cachexia remains an underdiagnosed and undertreated, complex condition which includes ‘objective’ components (e.g. inadequate food intake, weight loss, inactivity, loss of muscle mass and metabolic derangements, inducing catabolism)1,2 and ‘subjective’ components (e.g. anorexia, early satiety, taste alterations, chronic nausea, distress, fatigue and loss of concentration). Approximately half of all patients with advanced cancer experience cachexia.
Despite the improvement in clinical outcomes derived by the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours harbour EGFR-activating mutations, prognosis remains unfavourable because of the occurrence of either intrinsic or acquired resistance. We reviewed the published literature…
